Advances in this field have so far focused on expanding our understanding of the biological basis of HSP90 inhibition in NSCLC [39], as well as identifying biomarkers that predict response to inhibitors of these tumors [40]. This evidence concerns the gene HSP90AB1 and non-small cell lung carcinoma.